On Friday, Eton Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
Looking For The Best Stocks To Buy And Watch? Start Here
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they start a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Eton Pharmaceuticals has now climbed above a proper buy zone after breaking out from a 17.74 entry in a cup with handle. Keep in mind that it's a thinly traded stock, with average daily dollar volume under $8 million.
One weak spot is the company's 72 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A- shows heavy buying by institutional investors over the last 13 weeks.
The company posted a 600% EPS gain for Q1. Revenue growth increased 117%, up from 59% in the prior quarter. The company has now posted rising growth in each of the last three reports.
Eton Pharmaceuticals earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
